August 13th 2025
Consistent trends across prevalence, incidence, odds and time-to-event models suggest ocular mitochondrial disease may indicate neurodegenerative risk
Why patients with inflammatory bowel disease might need to see their ophthalmologist
January 4th 2023Ocular involvement in IBD is a rare extraintestinal manifestation, but may be critical because of its potential sight-threatening complications if not treated promptly and accurately, according to researchers.
The pathophysiology and pathomorphology of corneal ectasia: Part 4
November 14th 2022Corneal cross-linking (CXL) is improving all the time, although all protocols retain the basic requirements for oxygen, riboflavin and UV light. Recent developments mean that CXL at the slit lamp is feasible, which will improve access to the procedure.
Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate
August 13th 2022The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.
Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defects
July 10th 2022Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.
Positive topline data from Saturn-2 Phase 3 trial encourages Tarsus to file NDA in 2022
May 8th 2022TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
Predicting metastasis with novel prognostic liquid biopsy for uveal melanoma
May 4th 2022Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.